Short answer
Kyverna Therapeutics Inc (KYTX) filed an 8-K current report with the SEC on September 24, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Positive one-year KYSA-8 data for miv-cel in stiff person syndrome, supporting registrational development.
Kyverna Therapeutics Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Positive one-year KYSA-8 data for miv-cel in stiff person syndrome, supporting registrational development
- Positive longer-term Phase 2 KYSA-6 follow-up in generalized myasthenia gravis, strengthening durability evidence
- Conference call scheduled for September 24, 2026 at 8:00 a.m. Eastern Time to review trial results
Item EX-99.1 · Exhibit EX-99.1
- SPS 12-month data: 49% median T25FW improvement, with 95% sustaining clinically meaningful benefit
- 67% of pre-treatment walking-aid users remained independent, supporting meaningful reversal of disability
- 92% of SPS patients remained free from chronic immunotherapies at month 12
- gMG responses durable through 1.5 years, with 57% maintaining minimal symptom expression
- Rolling SPS BLA submission remains targeted for Q4 2026; gMG Phase 3 enrollment expected complete mid-2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Kyverna Therapeutics Inc 8-K filings
Get the next KYTX 8-K as it lands
Follow KYTX for push alerts, or ask the research agent what this filing means.